This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.
LOS ANGELES, CA - May 15, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company's investor relations site or by dialing +1-800-717-1738 (U.S.) or +1-646-307-1865 (international).
The earnings update comes shortly after news that NRx's wholly owned subsidiary, HOPE Therapeutics, signed a definitive agreement to acquire Kadima Neuropsychiatry Institute in La Jolla, California. Kadima is a profitable clinic and leader in psychedelic and neuroplastic research, offering treatments for suicidal depression, PTSD and other CNS conditions. It is expected to serve as the model for HOPE's national clinic rollout.
To view the full press release announcing the Kadima agreement, visit https://ibn.fm/sxSUl
About NRx Pharmaceuticals Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (preservative-free IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the U.S. National Institutes of Health and newly obtained data from French health authorities, licensed under a data-sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the U.S. FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the U.S. Patent and Trademark Office.
For further information, visit the company's website at www.NRxPharma.com
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to NRXP are available in the company's newsroom at https://ibn.fm/NRXP
Forward Looking Statements
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
About IBN
IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients.
IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions.
For more information, please visit www.IBN.fm
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Media Contact
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
View the original release on www.newmediawire.com